The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Anikina M.A.

Shindriaeva N.N.

Zimniakova O.S.

Psychotic disorders in Parkinson's disease and dementia with Lewy bodies

Authors:

Levin O.S., Anikina M.A., Shindriaeva N.N., Zimniakova O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6): 82‑88

Read: 10413 times

Download PDF (RU)
Contact the author
Table of contents

PSYCHOTIC DISORDERS IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES
PSYCHOTIC DISORDERS IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES

To cite this article:

Levin OS, Anikina MA, Shindriaeva NN, Zimniakova OS. Psychotic disorders in Parkinson's disease and dementia with Lewy bodies. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6):82‑88. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
The effect of bila­teral subthalamic nucleus deep brain stimulation on gait and bala­nce in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):94-101
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Abstract:

Keywords:

Parkinson disease
dementia with Lewy bodies
psychosis
cholinesterase inhibitors
atypical antipsychotics

Authors:

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Anikina M.A.

Shindriaeva N.N.

Zimniakova O.S.

Close metadata

References:

  1. Gavrilova S.I.Farmakoterapiya bolezni Al'tsgeimera. M: Pul's 2003; 337.
  2. Golubev V.L., Levin Ya.I., Vein A.M.Bolezn' Parkinsona i sindrom parkinsonizma. M: Medpress 1999; 415.
  3. Zakharov V.V., Lokshina A.B.Dementsiya s tel'tsami Levi. Nevrol zhurn 1998; 5: 57-61.
  4. Levin O.S.Psikhicheskie rasstroistva pri bolezni Parkinsona. V kn.: Ekstrapiramidnye rasstroistva. Rukovodstvo po diagnostike i lecheniyu. Pod red. V.N. Shtoka, I.A. Ivanovoi-Smolenskoi, O.S. Levina. M: Medpress-inform 2002; 233-256.
  5. Levin O.S.Bolezn' diffuznykh telets Levi. V kn.: Ekstrapiramidnye rasstroistva. Rukovodstvo po diagnostike i lecheniyu. Pod red.
  6. Levin O.S.Effektivnost' reminila pri dementsii s tel'tsami Levi. Zhurn nevrol i psikhiat 2005; 10: 10-15.
  7. Levin O.S.Dementsiya s tel'tsami Levi. Prakticheskie voprosy diagnostiki i lecheniya. M 2006.
  8. Levin O.S.Diagnostika i lechenie dementsii v klinicheskoi praktike. M: Medpress 2010; 256.
  9. Levin O.S., Fedorova N.V.Bolezn' Parkinsona. M: 2006; 256.
  10. Levin O.S., Amosova N.A., Naimushina T.V., Smolentseva I.G.Sravnitel'noe kliniko-neiropsikhologicheskoe issledovanie bol'nykh bolezn'yu Parkinsona i dementsiei s tel'tsami Levi. Zhurn nevrol i psikhiat 2004; 1: 37-42.
  11. Levin O.S., Naimushina T.V., Smolentseva I.G.Psikhoticheskie rasstroistva pri bolezni Parkinsona: kliniko-neiropsikhologicheskoe issledovanie. Nevrol zhurn 2002; 7: 5: 21-28.
  12. Levin O.S., Potsybina V.V., Amosova N.A. i dr.Rol' odnofotonnoi emissionnoi komp'yuternoi tomografii s 99Ts-GMAPO v nozologicheskoi diagnostike parkinsonizma. Nevrologicheskii vestnik im. Bekhtereva 2005; 5: 28-32.
  13. Preobrazhenskaya I.S., Yakhno N.N.Dementsiya s tel'tsami Levi. Nevrol zhurn 2004; 1: 4-11.
  14. Aarsland D., Larsen JP., Tandberg E., Laake K.Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatric Soc 2000; 48: 938-942.
  15. Burn D., Emre M., McKeith I., De Deyn P.P. et al.Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899-1907.
  16. Cummings J.L., Street J., Masterman D., Clark W.S.Efficicy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002; 13: 67-73.
  17. Devinsky O.Delusional misidentifications and duplications. J Neurology 2009; 72: 80-87.
  18. Emre M., Aarsland D., Brown R. et al.Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707.
  19. Emre M., Aarsland D., Albanese A. et al.Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
  20. Fabbrini G., Barbanti P., Aurilia C.Donepezil in the treatment of hallucinations and delusions in Parkinson disease. Neurol Sci 2002; 23: 41-43.
  21. Fenelon G., Goetz C.G. et al.Hallucinations in Parkinson disease in the prelevodopa era. J Neurol 2006; 66: 93-98.
  22. Fenelon G., Alves G.Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289: 12-17.
  23. Fernandez H.H., Lannon M.C., Friedman J.H., Abbott B.P.Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 579-581.
  24. Fox S.N., Chuang R., Brotchie J.M.Serotonin and Parkinson's disease. Movement Disorders 2009; 24: 1255-1266.
  25. Goetz C., Diederich N., Fenelon G.Psychosis in Parkinson disease. K.R. Chaudhuri et al (eds). Non-motor symptoms of Parkinson's disease. Oxford 2009; 147-163.
  26. Josephs K.A.Capgras syndrome and its relationship to neurodegenerative disease. Arch Neurol 2007; 64: 1762-1766.
  27. Haeske-Dewick H.C.Hallucinations in Parkinson's disease. Int J Geriatr Psych 1995; 10: 487-185.
  28. Harding A.J., Broe G., Halliday G.Visual hallucinations in Lewy bodies disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
  29. Hely M.A., Reid W. et al.The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement Disorders 2009; 23: 837-844.
  30. Ismaili M.S., Richard I.H.A reality test: how well do we understand psychosis in Parkinson's disease. J Neuropsychiatry and Clinical Neurosciences 2004; 16: 8-18.
  31. Kurita A., Murakami M., Takagi S. et al.Visual hallucinations and altered information processing in Parkinson disease and dementia with Lewy bodies. Movement disorders 2010; 10: 1002/mds22919.
  32. Marsh L.Psychosis in Parkinson's disease. Primary psychiatry 2005; 12: 56-62.
  33. Marsh L., Lysetsos C., Reich S.G.Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001; 42: 477-481.
  34. McKeith I.G., Burn D.J., Ballard C.G., Collerton D. et al.Dementia with Lewy bodies. SeminClin Neuropsychiatry 2003; 8: 46-57.
  35. McKeith I., Del Ser T., Spano P. et al.Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled study. Lancet 2000; 352: 2031-2036.
  36. McKeith I.G., Dickson D.W., Lowe J. et al.Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65: 1863-1872.
  37. McKeith I.G., Wesnes K.A., Perry E., Ferrara R.Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004; 18: 94-100.
  38. Mosimann U.P., Rowan E.N., Partington C.E. et al.Characteristics of visual hallucinations in Parkinson's disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153-160.
  39. Motsinger C.D., Gregory A.Perron. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physican 2003; 67: 2335-2340.
  40. Nagahama Y., Okina T., Suzuki N., Matsuda M.Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 2011; DOI:10.1093/brain/awp295.
  41. Ondo W.G., Tintner R., Voung K.D. et al.Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallutinations in Parkinson's disease. Movement Disorders 2005; 20: 958-963.
  42. Papapetropoulos S.Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease. J Neuropsychiatry and Clinical Neurosciences 2006; 18: 149-157.
  43. Poewe W.When a Parkinson's disease patient starts to hallucinate. Practical Neurology 2008; 8: 238-241.
  44. Prohorov T., Klein C., Minovich A. et al.The effect of quetiapine in psychotic parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 2006; 253: 171-175.
  45. Ravina B., Putt M., Farrar J.T.Donepizil for dementia in Parkinson's disease: a randomized, double blind, placebo-controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939.
  46. Ravina B., Marder K., Fernandez H.H. et al.Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Movement Disorders 2007; 8: 1061-1068.
  47. Ricci M., Guidoni S.V., Sepe-Monti M. et al.Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies and Alzheimer's disease. Arch Gerontol Geriatr 2009; 49: 101-104.
  48. Roane D.M., Pogers J.D., Robinson J.H., Feinberg T.E.Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10: 194-198.
  49. Shotbolt P., Samuel M., Fox C., David A.S.A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009; 5: 327-332.
  50. Tariot P.N., Scheneider L., Katz I.R. et al.Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14: 767-76.
  51. Uchikado, Hirotake, Lin et al.Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. Journal of neuropathology and experimental neurology 2006; 65: 685-697.
  52. Weintraub D., Morales K., Duda J. et al.Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. Parkinsonism Relat Disord 2006; 12: 427-431.
  53. Weintraub D., Hurtig H.Presentation and management of psychosis in Parkinson's disease. Am J Psychiatry 2007; 164: 1491-1498.
  54. Williams D.R., Lees A.J.Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. The Lancet Neurology ; 4: 605-610.
  55. Williams D.R., Warren J.P., Lees A.J.Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 2008; 79: 652-655.
  56. Wolters E.Ch.PD-related psychosis: pathophysiology with therapeutical strategies. J Neurol Transm 2006; 71: 31-37.
  57. Zahodne L.B., Fernandez H.H.Pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 2008; 25: 665-682.
  58. Zhong X.K., Taroit P.N., Mintzer J. et al.Quetiapine to treat agitation in dementia: a randomized, double blind placebo-controlled study. Current Alzheimer Research 2007; 4: 81-93.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.